Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

How We Prevent GVHD in High Risk Patients: Post Transplant Cyclophosphamide and Beyond

Joseph Cataquiz Rimando, Shannon R McCurdy, Leo Luznik

Blood blood.2021015129.

DOI: https://doi.org/10.1182/blood.2021015129

Published: 2022

Includes: Supplemental data

Journal Articles

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Blood (2022) 139 (10): 1452–1468.

DOI: https://doi.org/10.1182/blood.2021013443

Published: 2022

Includes: Supplemental data

Journal Articles

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Shannon R. McCurdy, Vedran Radojcic, Hua-Ling Tsai, Ante Vulic, Elizabeth Thompson, Sanja Ivcevic, Christopher G. Kanakry, Jonathan D. Powell, Brian Lohman, Djamilatou Adom, Sophie Paczesny, Kenneth R. Cooke, Richard J. Jones, Ravi Varadhan, Heather J. Symons, Leo Luznik

Blood (2022) 139 (4): 608–623.

DOI: https://doi.org/10.1182/blood.2021013054

Published: 2022

Includes: Supplemental data

Journal Articles

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

Andrew Matthews, Alexander E. Perl, Selina M. Luger, Daria V. Babushok, Noelle V Frey, Saar Gill, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, David L. Porter, Edward A. Stadtmauer, Alison W. Loren, Vikram R Paralkar, Ivan Maillard, David Margolis, Keith W. Pratz

Blood (2021) 138 (Supplement 1): 795.

DOI: https://doi.org/10.1182/blood-2021-149158

Published: 2021

Journal Articles

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Blood (2021) 138 (Supplement 1): 469.

DOI: https://doi.org/10.1182/blood-2021-153955

Published: 2021

Journal Articles

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Janna C. Minehart, Christopher Catania, Linda Perry, Mary Ellen Martin, Jacqueline Smith, Shannon R. McCurdy, Keith W. Pratz, Selina M. Luger, Colleen Timlin, Alexander E. Perl, Mindy Schuster, David L Porter, Alison W. Loren, Elizabeth O. Hexner, Noelle V Frey

Blood (2021) 138 (Supplement 1): 2888.

DOI: https://doi.org/10.1182/blood-2021-153920

Published: 2021

Journal Articles

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

Ephraim J. Fuchs, MD MBA, Shannon R McCurdy, MD, Scott R. Solomon, MD, Tao Wang, PhD, Michelle Kuxhausen, MS, Yvette L Kasamon, MD, MHD Monzr Al Malki, MD, Shahinaz Gadalla, MD PhD, Sophie Paczesny, MDPhD, Steven GE Marsh, BSc, PhD ARCS, Bronwen E. Shaw, PhD MRCP, FRCPath, Stephen R. Spellman, MS, Stephanie J. Lee, MDMPH, Effie Petersdorf, MD

Blood (2020) 136 (Supplement 1): 24–26.

DOI: https://doi.org/10.1182/blood-2020-140433

Published: 2020

Journal Articles

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide

Shannon R. McCurdy, Leo Luznik

Blood (2019) 134 (21): 1802–1810.

DOI: https://doi.org/10.1182/blood.2019001323

Published: 2019

Journal Articles

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Blood (2019) 134 (Supplement_1): 48.

DOI: https://doi.org/10.1182/blood-2019-125967

Published: 2019

Journal Articles

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Shannon R. McCurdy, MD, Shannon H. Gier, BS, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Alexander E. Perl, MD, Ivan Maillard, MD PhD, Keith W. Pratz, MD, David L. Porter, MD, Martin P. Carroll, MD, Phyllis A. Gimotty, PhD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 2209.

DOI: https://doi.org/10.1182/blood-2019-124468

Published: 2019

Journal Articles

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Christine M. McMahon, MD, Nya Nelson, MD PhD, Alex Ganetsky, PharmD, James K. Mangan, MD PhD, Noelle V. Frey, MD, Alexander E. Perl, MD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alison W. Loren, MD MS, Elizabeth O. Hexner, MD MS, Adam Bagg, MD, Jennifer J.D. Morrissette, PhD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4785.

DOI: https://doi.org/10.1182/blood-2018-99-116415

Published: 2018

Journal Articles

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Benjamin M Manning, MD PhD, Robyn T Sussman, PhD, Safoora Deihimi, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, Selina Luger, MD, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Jennifer J.D. Morrissette, PhD, Alexander E. Perl, MD, Edward A. Stadtmauer, MD FACP, David L. Porter, MD, Saar I. Gill, MD PhD

Blood (2018) 132 (Supplement 1): 2134.

DOI: https://doi.org/10.1182/blood-2018-99-117410

Published: 2018

Journal Articles

Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents

Gee Youn (Geeny) Kim, PharmD, Jonathan Burns, PharmD, Craig W. Freyer, PharmD, Keith Hamilton, MD, Mindy Schuster, MD MSCE, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD, Alison W. Loren, MD MS

Blood (2018) 132 (Supplement 1): 5512.

DOI: https://doi.org/10.1182/blood-2018-99-119168

Published: 2018

Journal Articles

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Colleen Timlin, PharmD, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, Selina Luger, MD, Jacqueline Smith, MSN, CRNP, Edward Stadtmauer, David L. Porter, MD

Blood (2018) 132 (Supplement 1): 5696.

DOI: https://doi.org/10.1182/blood-2018-99-111550

Published: 2018

Journal Articles

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Mitchell E. Hughes, PharmD, Tracy M. Krause, PharmD, Colleen Timlin, PharmD, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4023.

DOI: https://doi.org/10.1182/blood-2018-99-112604

Published: 2018

Journal Articles

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Blood (2017) 130 (Supplement 1): 2593.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2593.2593

Published: 2017

Journal Articles

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Clio E Franklin, MBBS, BSc, MRCP, Margaret M. Showel, MD, Hua-Ling Tsai, ScM, Ravi Varadhan, PhD, Shannon R. McCurdy, MD, Douglas E. Gladstone, MD, Richard J. Jones, MD, Amy E. DeZern, MD

Blood (2017) 130 (Suppl_1): 849.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.849.849

Published: 2017

Journal Articles

Selecting between HLA-Matched Siblings and HLA- Haploidentical Related Donors for Acute Leukemia in the Era of Post-Transplant Cyclophosphamide: The Center for International Blood and Marrow Transplant Registry and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant

Blood (2017) 130 (Suppl_1): 851.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.851.851

Published: 2017

Journal Articles

Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide

Shannon R. McCurdy, MD, Christopher G. Kanakry, MD, Hua-Ling Tsai, ScM, Javier Bolaños-Meade, MD, Ephraim J. Fuchs, MD MBA, Gary Rosner, ScD, Richard J. Jones, MD, Leo Luznik, MD

Blood (2017) 130 (Supplement 1): 216.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.216.216

Published: 2017

Journal Articles

Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT

Blood (2017) 130 (Supplement 1): 4516.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4516.4516

Published: 2017

NARROW

How We Prevent GVHD in High Risk Patients: Post Transplant Cyclophosphamide and Beyond

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide

Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only